<p>Boothbay Fund Management LLC 在最近向美国证券交易委员会提交的 13F 报告中表示，在第四季度将其在 Cencora, Inc. (NYSE:COR - 免费报告) 的持仓削减了 95.7%。该基金在此期间出售了 30,065 股后，持有该公司 1,359 股股票。根据其最近向美国证券交易委员会的报告，Boothbay Fund Management LLC 在 Cencora 的持股价值为 305,000 美元。</p>
<ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
<p>其他对冲基金也对该公司的股份进行了增持或减持。Susquehanna Fundamental Investments LLC 在第四季度新购入了价值约 1,392,000 美元的 Cencora 股票。Coldstream Capital Management Inc. 在第四季度将其在 Cencora 的持股增加了 3.0%。Coldstream Capital Management Inc. 目前持有该公司 3,399 股股票，价值 764,000 美元，此前在上个季度又购买了 100 股。Hancock Whitney Corp 在第四季度将其在 Cencora 的持股增加了 0.9%。Hancock Whitney Corp 目前持有该公司 75,035 股股票，价值 16,859,000 美元，此前在此期间又购买了 671 股。Voya Investment Management LLC 在第四季度将其在 Cencora 的持仓提高了 5.8%。Voya Investment Management LLC 目前持有该公司 310,646 股股票，价值 69,796,000 美元，此前在上个季度又购买了 17,064 股。最后，Coppell Advisory Solutions LLC 在第四季度将其在 Cencora 的持股增加了 97.9%。Coppell Advisory Solutions LLC 目前持有该公司 384 股股票，价值 86,000 美元，此前在上个季度又购买了 190 股。机构投资者持有该公司 97.52% 的股票。</p>
<h2>分析师评级变动</h2>
<p>多位股票分析师最近对该股发表了评论。瑞银集团将 Cencora 的股票目标价从 298.00 美元上调至 335.00 美元，并在周二的研究报告中给予该股 &#34;买入&#34; 评级。富国银行将 Cencora 的股票目标价从 251.00 美元上调至 274.00 美元，并在 3 月 14 日的报告中给予该股 &#34;持平&#34; 评级。摩根大通将 Cencora 的目标价从 289.00 美元上调至 301.00 美元，并在 1 月 24 日的研究报告中给予该公司 &#34;增持&#34; 评级。Evercore ISI 将 Cencora 的股票目标价从 270.00 美元上调至 280.00 美元，并在 2 月 6 日的报告中给予该股 &#34;跑赢大盘&#34; 评级。最后，美国银行将 Cencora 的股票目标价从 270.00 美元上调至 285.00 美元，并在 4 月 11 日的报告中给予该股 &#34;中性&#34; 评级。两位投资分析师对该股给予了持有评级，八位分析师给予了买入评级。根据 MarketBeat，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标价为 290.00 美元。</p>
<ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
<p><strong>查看我们关于 Cencora 的最新研究报告</strong></p>
<h2>Cencora 价格表现</h2>
<p>Cencora (NYSE:COR) 的股票在周五开盘时为 292.17 美元。该公司的市值为 566.6 亿美元，市盈率为 41.56，市盈率/增长比率为 1.31，贝塔值为 0.55。该公司的 50 日移动平均价格为 272.65 美元，200 日移动平均价格为 251.43 美元。该公司的流动比率为 0.92，速动比率为 0.54，债务与股本比率为 16.40。Cencora, Inc. 的 1 年最低价为 214.77 美元，1 年最高价为 296.65 美元。</p>
<ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
<p>Cencora (NYSE:COR - 获取免费报告) 最近在 2 月 5 日星期三发布了其财报。该公司报告每股收益 (EPS) 为 3.73 美元，超出分析师一致预期的 3.50 美元，超出幅度为 0.23 美元。Cencora 的股本回报率为 328.62%，净利润率为 0.46%。股票研究分析师预计 Cencora, Inc. 在当前财政年度将发布每股收益 15.37 美元。</p>
<h2>Cencora 股息公告</h2>
<p>该公司最近还宣布了一项季度股息，该股息于 3 月 3 日星期一支付。记录在案的投资者在 2 月 14 日星期五获得了 0.55 美元的股息。该股息的除息日期为 2 月 14 日星期五。这代表着每年 2.20 美元的股息和 0.75% 的收益率。Cencora 的派息比率为 31.29%。</p>
<h2>Cencora 的内部买卖</h2>
<p>在相关消息中，董事长 Steven H. Collis 于 4 月 22 日星期二出售了 14,579 股 Cencora 股票。该股票以平均价格 281.81 美元出售，总交易额为 4,108,507.99 美元。交易后，董事长现在持有该公司 315,913 股股票，价值 89,027,442.53 美元。此次交易使其持股减少了 4.41%。该交易在美国证券交易委员会的备案中披露，相关信息可在此链接查看。此外，首席执行官 Robert P. Mauch 于 4 月 21 日星期一出售了 4,969 股该股票。该股票以平均价格 289.33 美元出售，总价值为 1,437,680.77 美元。交易完成后，首席执行官现在直接持有该公司 47,582 股股票，价值 13,766,900.06 美元。此次交易使其持股减少了 9.46%。该交易的披露信息可在此处找到。在上个季度，内部人士出售了价值 13,580,967 美元的 50,223 股公司股票。内部人士持有该公司 10.80% 的股票。</p>
<h2>关于 Cencora</h2>
<p>(免费报告)</p>
<p>Cencora, Inc. 采购和分销药品。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配备和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品批准后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>Meta 第一季度财报亮相 - 注意第二季度的关税影响</li>
<li>最佳股票推荐：低于 5.00 美元</li>
<li>亚马逊财报：2 个值得喜爱的理由，1 个需要谨慎的理由</li>
<li>复利是如何计算的？</li>
<li>Palantir 财报：1 个看涨信号和 1 个关注领域</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
<p>在考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>根据 Boothbay Fund Management LLC 最近向 SEC 提交的 13F 文件，该基金在第四季度将其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）中的持仓削减了 95.7%。在此期间，该基金在出售了 30,065 股后，持有该公司 1,359 股股票</p>

<p>Boothbay Fund Management LLC trimmed its position in Cencora, Inc. (NYSE:COR - Free Report) by 95.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,359 shares of the company's stock after selling 30,065 shares during the period. Boothbay Fund Management LLC's holdings in Cencora were worth $305,000 as of its most recent filing with the SEC.</p>
<div class="lb-trans"><p>Boothbay Fund Management LLC 在最近向美国证券交易委员会提交的 13F 报告中表示，在第四季度将其在 Cencora, Inc. (NYSE:COR - 免费报告) 的持仓削减了 95.7%。该基金在此期间出售了 30,065 股后，持有该公司 1,359 股股票。根据其最近向美国证券交易委员会的报告，Boothbay Fund Management LLC 在 Cencora 的持股价值为 305,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中，标准普尔 500 指数的前三大赢家</li>
</ul>
</div><p>Other hedge funds have also added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Cencora during the fourth quarter worth about $1,392,000. Coldstream Capital Management Inc. increased its holdings in Cencora by 3.0% during the fourth quarter. Coldstream Capital Management Inc. now owns 3,399 shares of the company's stock worth $764,000 after buying an additional 100 shares during the last quarter. Hancock Whitney Corp raised its holdings in shares of Cencora by 0.9% in the 4th quarter. Hancock Whitney Corp now owns 75,035 shares of the company's stock valued at $16,859,000 after purchasing an additional 671 shares during the period. Voya Investment Management LLC lifted its position in shares of Cencora by 5.8% in the fourth quarter. Voya Investment Management LLC now owns 310,646 shares of the company's stock valued at $69,796,000 after buying an additional 17,064 shares during the last quarter. Finally, Coppell Advisory Solutions LLC increased its holdings in shares of Cencora by 97.9% in the fourth quarter. Coppell Advisory Solutions LLC now owns 384 shares of the company's stock valued at $86,000 after purchasing an additional 190 shares during the last quarter. Institutional investors own 97.52% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金也对该公司的股份进行了增持或减持。Susquehanna Fundamental Investments LLC 在第四季度新购入了价值约 1,392,000 美元的 Cencora 股票。Coldstream Capital Management Inc. 在第四季度将其在 Cencora 的持股增加了 3.0%。Coldstream Capital Management Inc. 目前持有该公司 3,399 股股票，价值 764,000 美元，此前在上个季度又购买了 100 股。Hancock Whitney Corp 在第四季度将其在 Cencora 的持股增加了 0.9%。Hancock Whitney Corp 目前持有该公司 75,035 股股票，价值 16,859,000 美元，此前在此期间又购买了 671 股。Voya Investment Management LLC 在第四季度将其在 Cencora 的持仓提高了 5.8%。Voya Investment Management LLC 目前持有该公司 310,646 股股票，价值 69,796,000 美元，此前在上个季度又购买了 17,064 股。最后，Coppell Advisory Solutions LLC 在第四季度将其在 Cencora 的持股增加了 97.9%。Coppell Advisory Solutions LLC 目前持有该公司 384 股股票，价值 86,000 美元，此前在上个季度又购买了 190 股。机构投资者持有该公司 97.52% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of equities analysts recently commented on the stock. UBS Group raised their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Wells Fargo &amp; Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an &#34;equal weight&#34; rating in a report on Friday, March 14th. JPMorgan Chase &amp; Co. upped their price objective on Cencora from $289.00 to $301.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, January 24th. Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, February 6th. Finally, Bank of America lifted their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a &#34;neutral&#34; rating in a report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $290.00.</p>
<div class="lb-trans"><p>多位股票分析师最近对该股发表了评论。瑞银集团将 Cencora 的股票目标价从 298.00 美元上调至 335.00 美元，并在周二的研究报告中给予该股 &#34;买入&#34; 评级。富国银行将 Cencora 的股票目标价从 251.00 美元上调至 274.00 美元，并在 3 月 14 日的报告中给予该股 &#34;持平&#34; 评级。摩根大通将 Cencora 的目标价从 289.00 美元上调至 301.00 美元，并在 1 月 24 日的研究报告中给予该公司 &#34;增持&#34; 评级。Evercore ISI 将 Cencora 的股票目标价从 270.00 美元上调至 280.00 美元，并在 2 月 6 日的报告中给予该股 &#34;跑赢大盘&#34; 评级。最后，美国银行将 Cencora 的股票目标价从 270.00 美元上调至 285.00 美元，并在 4 月 11 日的报告中给予该股 &#34;中性&#34; 评级。两位投资分析师对该股给予了持有评级，八位分析师给予了买入评级。根据 MarketBeat，该公司目前的平均评级为 &#34;适度买入&#34;，共识目标价为 290.00 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的 4 个理由</li>
</ul>
</div><p><strong>View Our Latest Research Report on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Cencora 的最新研究报告</strong></p>
</div><h2>Cencora Price Performance</h2>
<div class="lb-trans"><h2>Cencora 价格表现</h2>
</div><p>Shares of NYSE COR opened at $292.17 on Friday. The firm has a market capitalization of $56.66 billion, a P/E ratio of 41.56, a P/E/G ratio of 1.31 and a beta of 0.55. The firm's 50-day moving average price is $272.65 and its 200-day moving average price is $251.43. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65.</p>
<div class="lb-trans"><p>Cencora (NYSE:COR) 的股票在周五开盘时为 292.17 美元。该公司的市值为 566.6 亿美元，市盈率为 41.56，市盈率/增长比率为 1.31，贝塔值为 0.55。该公司的 50 日移动平均价格为 272.65 美元，200 日移动平均价格为 251.43 美元。该公司的流动比率为 0.92，速动比率为 0.54，债务与股本比率为 16.40。Cencora, Inc. 的 1 年最低价为 214.77 美元，1 年最高价为 296.65 美元。</p>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
</div><p>Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora (NYSE:COR - 获取免费报告) 最近在 2 月 5 日星期三发布了其财报。该公司报告每股收益 (EPS) 为 3.73 美元，超出分析师一致预期的 3.50 美元，超出幅度为 0.23 美元。Cencora 的股本回报率为 328.62%，净利润率为 0.46%。股票研究分析师预计 Cencora, Inc. 在当前财政年度将发布每股收益 15.37 美元。</p>
</div><h2>Cencora Dividend Announcement</h2>
<div class="lb-trans"><h2>Cencora 股息公告</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's payout ratio is 31.29%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，该股息于 3 月 3 日星期一支付。记录在案的投资者在 2 月 14 日星期五获得了 0.55 美元的股息。该股息的除息日期为 2 月 14 日星期五。这代表着每年 2.20 美元的股息和 0.75% 的收益率。Cencora 的派息比率为 31.29%。</p>
</div><h2>Insider Buying and Selling at Cencora</h2>
<div class="lb-trans"><h2>Cencora 的内部买卖</h2>
</div><p>In related news, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares of the company's stock, valued at $89,027,442.53. The trade was a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the sale, the chief executive officer now directly owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,223 shares of company stock worth $13,580,967. Insiders own 10.80% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事长 Steven H. Collis 于 4 月 22 日星期二出售了 14,579 股 Cencora 股票。该股票以平均价格 281.81 美元出售，总交易额为 4,108,507.99 美元。交易后，董事长现在持有该公司 315,913 股股票，价值 89,027,442.53 美元。此次交易使其持股减少了 4.41%。该交易在美国证券交易委员会的备案中披露，相关信息可在此链接查看。此外，首席执行官 Robert P. Mauch 于 4 月 21 日星期一出售了 4,969 股该股票。该股票以平均价格 289.33 美元出售，总价值为 1,437,680.77 美元。交易完成后，首席执行官现在直接持有该公司 47,582 股股票，价值 13,766,900.06 美元。此次交易使其持股减少了 9.46%。该交易的披露信息可在此处找到。在上个季度，内部人士出售了价值 13,580,967 美元的 50,223 股公司股票。内部人士持有该公司 10.80% 的股票。</p>
</div><h2>About Cencora</h2>
<div class="lb-trans"><h2>关于 Cencora</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.</p>
<div class="lb-trans"><p>Cencora, Inc. 采购和分销药品。该公司的美国医疗解决方案部门向急性护理医院和健康系统、独立和连锁零售药房、邮购药房、医疗诊所、长期护理和替代地点药房及其他客户分销药品、非处方医疗产品、家庭医疗用品和设备及相关服务；提供药房管理、人员配备和其他咨询服务；向零售和机构医疗提供者提供供应管理软件；向各种机构和零售医疗提供者提供包装解决方案；提供临床试验支持、产品批准后和商业化支持服务；为生物技术和制药制造商提供数据分析、结果研究和其他服务；向伴侣动物和生产动物市场提供药品、疫苗、驱虫剂、诊断产品、微饲料成分及其他产品；以及向制造商提供销售团队服务。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2</li>
<li>Best Stocks Under $5.00</li>
<li>Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious</li>
<li>How is Compound Interest Calculated?</li>
<li>Palantir Earnings: 1 Bullish Signal and 1 Area of Concern</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cencora</li>
<li>股息贵族名单中的最佳：通过贵族指数积累财富</li>
<li>Meta 第一季度财报亮相 - 注意第二季度的关税影响</li>
<li>最佳股票推荐：低于 5.00 美元</li>
<li>亚马逊财报：2 个值得喜爱的理由，1 个需要谨慎的理由</li>
<li>复利是如何计算的？</li>
<li>Palantir 财报：1 个看涨信号和 1 个关注领域</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cencora 吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Boothbay Fund Management LLC 持有 Cencora, Inc. (NYSE:COR) 价值 305,000 美元的股票